Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06310551 · ClinicalTrials.gov registry record · Phase 1
First Time in Human Study of Long Acting VH4524184 Formulations
A Phase 1 study of HIV Infections, sponsored by ViiV Healthcare.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 268
- Enrollment target
- 2
- Study locations
NCT06310551 is a Phase 1 study of HIV Infections that is actively recruiting participants, run by ViiV Healthcare. The registered enrollment target is 268 participants, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (40% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT06310551, a Phase 1 study of HIV Infections, is actively recruiting participants, sponsored by ViiV Healthcare.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 268 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to identify 1 or more doses of parenterally administered VH4524184 that are safe, well tolerated and yield a PK drug exposure profile necessary to deliver a long-acting antiretroviral therapy for the treatment of HIV-1 infection.
Conditions Studied
Interventions
- DRUG rHuPH20
- DRUG Oral VH4524184
- DRUG VH4524184 Formulation A SC
- DRUG Placebo Formulation A SC
- DRUG VH4524184 Formulation B SC
Study Locations (2)
Kansas
- GSK Investigational Site - Lenexa
Texas
- GSK Investigational Site - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 268 participants |
| Start Date | 2024-03-21 |
| Est. Completion | 2028-01-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06310551
The ClinicalTrials.gov registry entry for NCT06310551 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 268 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (40% lower). The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 5 interventions - of which rHuPH20 is the first listed.
NCT06310551 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Kansas, Texas.
Frequently Asked Questions
What is clinical trial NCT06310551 about?
NCT06310551 is a clinical study titled "First Time in Human Study of Long Acting VH4524184 Formulations". The purpose of this study is to identify 1 or more doses of parenterally administered VH4524184 that are safe, well tolerated and yield a PK drug exposure profile necessary to deliver a long-acting antiretroviral therapy for the treatment of HIV-1 infection.
What is the current status of trial NCT06310551?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 268 participants. The study started on 2024-03-21. Estimated completion is 2028-01-21.
What conditions does trial NCT06310551 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT06310551?
The interventions under investigation include: rHuPH20 (DRUG), Oral VH4524184 (DRUG), VH4524184 Formulation A SC (DRUG), Placebo Formulation A SC (DRUG), VH4524184 Formulation B SC (DRUG).
Who is sponsoring clinical trial NCT06310551?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06310551 being conducted?
This trial has 2 study locations across Kansas, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CAR-T Cells for HIV Infection
RECRUITING · Phase 1
-
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
RECRUITING · Phase 1
-
Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706
RECRUITING · Phase 1
-
Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics
RECRUITING · Phase 1
-
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
RECRUITING · Phase 1
-
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of VH4011499 Compared to Placebo in Adults Without HIV
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.